Category: Manufacturing

June 15, 2022

When vaccines became available earlier in the COVID-19 pandemic, countries vied for supply contracts. However, as the need for vaccines begins to slow in Europe, some countries want to amend their contracts to reduce spending and to prevent receiving more […]

June 14, 2022

Alnylam, a pioneer in the drugmaking method known as RNA interference, has climbed the biotech industry ranks over the last two decades. After solving challenges associated with delivering these treatments into the body, Alnylam has become one of the sector’s […]

June 9, 2022

While recent years have seen scientists make major advances in cutting-edge treatments such as gene and cell therapies, manufacturing remains a significant hurdle. The complex, multi-step processes required are beyond the capabilities of a traditional pharmaceutical plant. That’s where Resilience […]

June 9, 2022

Regenxbio recently celebrated the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility. “Launching operations at our Manufacturing Innovation Center is an important milestone in the evolution of REGENXBIO,” said Kenneth T. Mills, president and CEO of REGENXBIO. […]

June 2, 2022

Sana Biotechnology, which raised a whopping $588 million in its initial public offering last year, has inked a deal for new manufacturing space. The preclinical-stage biotech is ditching plans to run its manufacturing operations in Fremont, California, and instead plans […]

May 16, 2022

Catalent, a company enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, has introduced its new, UpTempo Virtuoso platform process for the development and CGMP manufacturing of adeno-associated […]

April 25, 2022

The FDA’s Office of Prescription Drug Promotion (OPDP) wants to find out how patients and physicians weigh the tradeoffs between risks and benefits when starting a new prescription drug. What characteristics influence treatment choices and how do people reach the […]

April 22, 2022

Catalent announced on April 21, 2022 that it is planning a multi-year $350 million investment at its facility in Bloomington, Ind. to expand its biologics drug substance and drug product manufacturing capabilities. The project will include the additions of new […]

April 21, 2022

Formerly known as Seattle Genetics, Seagen has grown to become one of the industry’s largest biotechs, with a market value of $26 billion. Seagen’s business is built on antibody drug conjugates, or ADCs, a type of medicine that uses laboratory-engineered […]

April 21, 2022

Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a new manufacturing facility in the Research Triangle Park area of North Carolina. Construction of the 25,972 square-foot plant is set to begin this […]

April 13, 2022

VectorBuilder, a global gene delivery solutions company, announced on April 11, 2022 the construction of a new $500 million R&D and manufacturing center in Guangzhou, China. The ‘Gene Delivery Research and Manufacturing Campus’ will aid in the growth of the […]

April 7, 2022

Catalent announced on April 6, 2022 that it has acquired Vaccine Manufacturing and Innovation Centre UK Limited’s biologics development and manufacturing facility currently under construction near Oxford, United Kingdom. Catalent plans to invest up to US$160 million (£120 million) into […]